BVS · Bioventus Inc.

Track BVS — free

$13.13 -0.32 (-2.38%) At close · Oct 2

Russell 2000 member Rebalance outlook locked

Market Cap

$1.18B

84.09M

Volume · Oct 2 362.37K Avg daily vol (3M) 658.6K

Up next

Next earnings call

Nov 4, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Aug 5, 2026

Q2 2026 earnings call transcript

call held Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$581.85M

Trailing 12 months

Net income (TTM)

$54.46M

Trailing 12 months

Revenue growth YoY

+3.8%

Year over year

Operating margin

10.0%

Trailing 12 months

P / E (TTM)

17.1

Trailing earnings · reciprocal yield 5.9%

FCF yield

8.0%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$219.00M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+3.4%

Year over year · more shares

Price change (1Y)

+95.7%

Trailing year

Short interest

3.5%

Latest settlement · 5.7 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026

Q2 FY26

TL;DR. Bioventus reported Q2 revenue of $153.2 million (up 4%) driven by double-digit Pain Treatments growth, reaffirmed full-year 2026 guidance, made a $20 million discretionary debt prepayment, and initiated a review of strategic alternatives following an unsolicited acquisition proposal.

Bullish

+ Made a $20.0 million discretionary principal prepayment on term loan, with debt pay down of $46 million YTD and leverage below 2x
+ Board initiated review of strategic alternatives following unsolicited acquisition proposal and multiple expressions of interest
+ PRP and PNS businesses showed accelerated capital placements, new customer wins, and positive market feedback

Bearish

− Company took proactive channel actions in BGS during Q2 that had a temporary impact on the business

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +28%

above

Price vs 50-day avg −4%

below

RSI (14) 44

neutral

MACD trend Negative

52-week position 76%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −9%

trailing

6-month return +39%

trailing

YTD return +76%

this year

Relative strength +27%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $14 › 200d $10 — 50d above 200d

Institutional flow Flat

1 of 157 funds reported for Sep 30 · net 0 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

3.49% of float · ▲ +13.6% MoM · 5.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

157 holders — near 3-yr high, broad support

Squeeze score 66

elevated · 0–100

Fundamentals

Strong

Revenue growth −1%

Y/Y

Gross margin 68%

expanding

EPS growth +159%

Y/Y

Free cash flow $72.1M

Valuation P/E 18.2

below peers

Balance sheet $242.7M

net debt

Quant / Vol

risk profile

High

Volatility 51%

annualized · 1-yr

Max drawdown −28%

past year

ATR 3.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 3 of last 3

Latest guidance · from the 8-K filed Aug 5, 2026

Net sales · twelve months ending December 31, 2026 Initiated $600M – $610M

prior FY $568.09M midpoint +6.5% Y/Y

Adjusted EPS · twelve months ending December 31, 2026 Non-GAAP Initiated $0.75 – $0.79

Guided vs delivered · last 3 settled

Net sales full-year 2024

guided $535M – $550M

guided $535M – $550M $573.28M Beat +5.7%

Net sales twelve months ending December 31, 2023

guided $498M – $505M

guided $498M – $505M $512.35M Beat +2.2%

2021 revenue 2021

guided $425M – $430M

guided $425M – $430M $430.9M Beat +0.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 5 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+28% Bullish

Price vs 50-day avg

−4% Neutral

RSI (14)

44 Neutral

MACD trend

Negative Bearish

52-week position

76% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $14 › 200d $10 — 50d above 200d

Institutional flow Flat

1 of 157 funds reported for Sep 30 · net 0 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

3.49% of float · ▲ +13.6% MoM · 5.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

157 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $7 Now $13 · 76% Range high $15

vs 200-day avg +28% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
International Segment Adjusted EBITDA non-GAAP	$4.78M	Three Months Ended June 27, 2026 filing	—
U.S. Segment Adjusted EBITDA non-GAAP	$30.49M	Three Months Ended June 27, 2026 filing	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
BVS Bioventus Inc. this stock	$1.18B	+76.5%	-0.9%	18.2	3.5%
ABT Abbott Laboratories	$174.90B	-22.2%	+5.7%	28.1	1.1%
MDT Medtronic plc	$113.38B	-10.1%	+8.4%	21.8	1.3%
SYK Stryker Corp	$104.47B	-21.6%	+11.2%	28.2	2.0%
BSX Boston Scientific Corp	$63.59B	-55.3%	+12.5%	17.8	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders

Holders

157

% held: 64.3%
Reported: 1 of 157
Top holder: Essex Woodlands Managemen…

Held Float

View

Held by Funds

Fund positions

168

View

Short & Settlement

Short Interest Rising

Shares short

2.9M

Days to cover: 5.7d
Change: +349.8K sh

View

Short Volume

Short vol %

70%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $1.2K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

40.2%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$568.1M

Net income (FY): $22.7M
EPS diluted: $0.33

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 5, 2026
This year: 10

View

Proposed Sales

Value

$105.7K

Shares: 12.0K
Filed: Mar 11, 2026

View

Earnings & Events

Webcasts

Last webcast

Aug 5, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
BVS	-4.9%	-8.6%	+39.4%	-3.7%	+76.5%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-4.7%	-8.1%	+27.2%	-4.6%	+63.6%

Key facts CIK 1665988 CUSIP 09075A108 13F (30d) 4 filings 4 filers Visit website Investor relations

BVS · Bioventus Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance